Pulse Biosciences Completes Enrollment in PRECISE-BTN Thyroid Nodule Study
PLSE has more than doubled off its 52-week low of $12.56.
Summary
Enrollment is complete in the PRECISE-BTN clinical study for benign thyroid nodules, with the original design doubled to 100 patients. The first patient has completed 12-month follow-up, and preliminary data is expected at an upcoming medical conference.
Key Events · Product Development and Regulatory · PLSE
-
PRECISE-BTN Enrollment Complete
Enrollment reached 100 patients, double the original 50-patient design, across three U.S. sites (Sarasota Memorial, NYU Langone, Weill Cornell) in approximately 12 months.
-
First Patient Completes 12-Month Follow-Up
The first enrolled patient completed the final 12-month follow-up visit in August 2026 at Sarasota Memorial under Dr. Ralph P. Tufano.
-
Data Readout Timeline
Preliminary data is planned for presentation at an upcoming medical society conference, with full data expected upon completion of 12-month follow-up for all patients.
-
Study Endpoints
Endpoints include safety, targeted nodule volume reduction, symptomatic relief, hormone normalization, and quality-of-life improvements.
Analysis · PLSE · Industrial Applications And Services
Enrollment is now complete in the PRECISE-BTN pivotal study for the nPulse Vybrance system, with the original design doubled from 50 to 100 patients across three U.S. sites. The first patient has already finished the 12-month follow-up, so the study is fully enrolled and the clock is running on final data. This is a meaningful de-risking event for the thyroid nodule indication — completing enrollment removes a key execution risk and sets a clear path to data readout. Preliminary data is planned for presentation at an upcoming medical conference, with full data expected after all patients complete 12-month follow-up.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 32% of the 2040 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PLSE was trading at $54.21 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $12.56 to $58.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.